AOLS / Aeolus Pharmaceuticals, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

AOLS / Aeolus Pharmaceuticals, Inc. FORM 15-12G

Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 0-50481 Aeolus Pharmaceuticals, Inc. (Exact name of registrant as

AOLS / Aeolus Pharmaceuticals, Inc. QUARTERLY REPORT (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017.

Aeolus Pharmaceuticals QUARTERLY REPORT (Quarterly Report)

Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017.

Other Events

Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 24, 2017 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commission File Number) (IRS Emp

Aeolus Pharmaceuticals QUARTERLY REPORT (Quarterly Report)

Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2016.

Aeolus Pharmaceuticals NT 10-Q

templatent10q.htm OMB APPROVAL OMB Number: 3235-0058 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Expires: October 31, 2018 Estimated average burden hours per response.......2.50 FORM 12b-25 SEC FILE NUMBER 0-50481 CUSIP NUMBER NOTIFICATION OF LATE FILING 00765G109 (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Peri

Aeolus Pharmaceuticals AMENDMENT TO ANNUAL REPORT (Annual Report)

10-K/A 1 aols10ka.htm AMENDMENT TO ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the tran

Aeolus Pharmaceuticals AEOLUS PHARMACEUTICALS 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-K (MARK ONE) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-50481 AEOLUS PHARMACEUT

LIST OF SUBSIDIARIES

EX-21.1 2 exh211.htm EXHIBIT 21.1 Exhibit 21.1 LIST OF SUBSIDIARIES Aeolus Sciences, Inc., a Delaware corporation

As filed with the Securities and Exchange Commission on December 20, 2016

As filed with the Securities and Exchange Commission on December 20, 2016 Registration No.

September 13, 2016

EX-16.1 2 exh161.htm EXHIBIT 16.1 Exhibit 16.1 September 13, 2016 U.S. Securities and Exchange Commission Office of the Chief Accountant 100 F Street, NE Washington, DC 20549 Re: Aeolus Pharmaceuticals, Inc. File No. 0-50481 Dear Sir or Madam: We have read Item 4.01 of Form 8-K of Aeolus Pharmaceuticals, Inc. dated September 8, 2016, and agree with the statements concerning our Firm contained ther

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

8-K 1 aeoluspharmaceuticalsinc8k.htm AEOLUS PHARMACEUTICALS, INC. 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2016 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (S

Aeolus Pharmaceuticals AEOLUS PHARMACEUTICALS, INC. 10-Q (Quarterly Report)

10-Q 1 aeolus10q.htm AEOLUS PHARMACEUTICALS, INC. 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to . Co

Regulation FD Disclosure

8-K 1 aeolus8k.htm AEOLUS PHARMACEUTICALS 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2016 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of

Aeolus Pharmaceuticals AEOLUS PHARMACEUTICALS, INC. 10-Q/A (Quarterly Report)

10-Q/A 1 aeolus10q.htm AEOLUS PHARMACEUTICALS, INC. 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A Amendment No. 1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transit

Aeolus Pharmaceuticals AEOLUS PHARMACEUTICALS, INC. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016.

Aeolus Pharmaceuticals AEOLUS PHARMACEUTICALS, INC. SCHEDULE 14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement Aeolus Pharmaceuticals, Inc. (Name of Re

Aeolus Pharmaceuticals AEOLUS PHARMACEUTICALS, INC. SCHEDULE 14 C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement Aeolus Pharmaceuticals, Inc. (Name of Re

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2016 (February 19, 2016) AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-504

AOLS / Aeolus Pharmaceuticals, Inc. / Biotechnology Value Fund L P - AMENDMENT NO. 3 TO THE SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 Aeolus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 00765G109 (CUSIP Numb

Joint Filing Agreement

EX-99.1 2 ex991to13ga307422022021616.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 16, 2016 with respect to the shares of Common Stock of Aeolus Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursu

AOLS / Aeolus Pharmaceuticals, Inc. 10-Q - Quarterly Report - AEOLUS PHARMACEUTICALS, INC. 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2015.

As filed with the Securities and Exchange Commission on February 12, 2016

As filed with the Securities and Exchange Commission on February 12, 2016 Registration No.

Aeolus Pharmaceuticals ESP

AEOLUS PHARMACEUTICALS, INC. 26361 Crown Valley Parkway, Suite 150 Mission Viejo, California 92691 (949) 481-9825 February 11, 2016 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3628 Re: Aeolus Pharmaceuticals, Inc. Amendment No. 1 to Registration Statement on Form S-1 File No. 333-209119 Ladies and Gentlemen: I

As filed with the Securities and Exchange Commission on January 26, 2016

As filed with the Securities and Exchange Commission on January 26, 2016 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 ____________ FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2015 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-50481 AEOLUS PHARMACEUT

LIST OF SUBSIDIARIES

EX-21.1 3 exh211.htm EXHIBIT 21.1 Exhibit 21.1 LIST OF SUBSIDIARIES Aeolus Sciences, Inc., a Delaware corporation

EX-4.13

Exhibit 4.13

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2015 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commi

John McManus

Exhibit 99.1 Contact: John McManus President and Chief Executive Officer Aeolus Pharmaceuticals, Inc. 1-(949) 481-9820 AEOLUS ANNOUNCES $6.75 MILLION PRIVATE PLACEMENT FINANCING Mission Viejo, CA ? December 15, 2015 - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced today that it

CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS SERIES C CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW

Exhibit 10.1 AEOLUS PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW AEOLUS PHARMACEUTICALS, INC., a Delaware corporation (the " Corporation "), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the " DGCL ") does her

AEOLUS PHARMACEUTICALS, INC. REGISTRATION RIGHTS AGREEMENT

Exhibit 10.2 AEOLUS PHARMACEUTICALS, INC. REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (the " Agreement") is made and entered into as of December 8, 2015 by and among Aeolus Pharmaceuticals, Inc., a Delaware corporation (the " Company"), and the "Purchasers" named in certain Securities Purchase Agreements by and among the Company and the Purchasers, dated as of an even date her

Unregistered Sales of Equity Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2015 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commi

AEOLUS PHARMACEUTICALS, INC. COMMON STOCK WARRANT

Exhibit 10.3 NEITHER THIS WARRANT NOR ANY OF THE SECURITIES ISSUABLE HEREUNDER HAVE BEEN REGISTERED UNDER THE SECURITIES ACT (AS DEFINED BELOW), OR APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT, OR (B) AN OPINION OF COUNSEL, IN A REASONABLY AC

Other Events

aeolustheraputics8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2015 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

10-Q 1 aeoluspharma10q.htm AEOLUS PHARMACEUTICALS, INC. 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015. ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015.

Other Events

aeolus8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2015 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953

AOLS / Aeolus Pharmaceuticals, Inc. / Biotechnology Value Fund L P - AMENDMENT NO.2 TO SCHEDULE 13G Passive Investment

SC 13G/A 1 sc13ga207422aeo12312014.htm AMENDMENT NO.2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Aeolus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.01 pa

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Amendment No. 2 to Schedule 13G dated February 17, 2015 with respect to the shares of Common Stock of Aeolus Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2014. o TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2014.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-K/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-K/A (Amendment No. 1) (MARK ONE) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2014 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-504

AOLS / Aeolus Pharmaceuticals, Inc. DEF 14C - - AEOLUS PHARMACEUTICALS, INC. DEF 14C

DEF 14C 1 aeolusdef14c.htm AEOLUS PHARMACEUTICALS, INC. DEF 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check appropriate box: o Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitiv

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-K (MARK ONE) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2014 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-50481 AEOLUS PHARMACEUT

LIST OF SUBSIDIARIES

Exhibit 21.1 LIST OF SUBSIDIARIES Aeolus Sciences, Inc., a Delaware corporation

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2014 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014.

- AEOLUS PHARMACEUTICALS, INC.

POS AM 1 aeolusposam.htm AEOLUS PHARMACEUTICALS, INC. As filed with the Securities and Exchange Commission on June 2, 2014 Registration No. 333-188670 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AEOLUS PHARMACEUTICALS, INC. (Exact Name of Issuer in Its Charter) Delaware 28

- AEOLUS PHARMACEUTICALS, INC. POS AM

As filed with the Securities and Exchange Commission on June 2, 2014 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014.

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2014 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commission

- AEOLUS PHARMACEUTICALS, INC. 14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check ` appropriate box: o Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement Aeolus Pharmaceuticals, Inc. (Name of

Aeolus Pharmaceuticals AEOLUS PHARMACEUTICALS, INC. 10-K/A (Annual Report)

10-K/A 1 aeolus10ka.htm AEOLUS PHARMACEUTICALS, INC. 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (MARK ONE) ýANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2013 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Fo

AOLS / Aeolus Pharmaceuticals, Inc. / Biotechnology Value Fund L P Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Aeolus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 00765G109 (CUSIP Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2013.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-K (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2013 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-50481 AEOLUS PHARMACEUT

LIST OF SUBSIDIARIES

EX-21.1 2 exh211.htm EXHIBIT 21.1 EXHIBIT 21.1 LIST OF SUBSIDIARIES Aeolus Sciences, Inc., a Delaware corporation

- AEOLUS PHARMACEUTICALS, INC. S-8

Registration No. 333- As filed with the Securities and Exchange Commission on August 21, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aeolus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 56-1953785 (I

PROSPECTUS SUPPLEMENT NO. 6 DATED August 15, 2013 (To Prospectus Dated March 13, 2013)

Prospectus Supplement Filed Pursuant to Rule 424(b)(3) Registration No. 333-181409 PROSPECTUS SUPPLEMENT NO. 6 DATED August 15, 2013 (To Prospectus Dated March 13, 2013) This Prospectus Supplement No. 6, dated August 15, 2013 (“Supplement No. 6”), filed by Aeolus Pharmaceuticals, Inc. (the “Company”), modifies and supplements certain information contained in the Company’s prospectus, dated March 1

PROSPECTUS SUPPLEMENT NO. 1 DATED August 15, 2013 (To Prospectus Dated June 14, 2013)

Prospectus Supplement Filed Pursuant to Rule 424(b)(3) Registration No. 333-188670 PROSPECTUS SUPPLEMENT NO. 1 DATED August 15, 2013 (To Prospectus Dated June 14, 2013) This Prospectus Supplement No. 1, dated August 15, 2013 (“Supplement No. 1”), filed by Aeolus Pharmaceuticals, Inc. (the “Company”), modifies and supplements certain information contained in the Company’s prospectus, dated June 14,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013.

Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-188670 Prospectus 30,591,501 Common Stock This prospectus relates to the offer and sale from time to time by the selling stockholders identified in this prospectus of up to 30,591,501 shares of our common stock, par value $0.01 per share. These shares include 14,462,000 shares of common stock and 14,462,000 shares issuable upon exercise of warr

-

Aeolus Pharmaceuticals, Inc. 26361 Crown Valley Parkway, Suite 150 Mission Viejo, California 92691 June 10, 2013 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Jeffrey Riedler Re: Aeolus Pharmaceuticals, Inc. Registration Statement Form S-1 (File No. 333-188670) Request for Acceleration Dear Mr. Riedler: Pursuan

- AEOLUS PHARMACEUTICALS, INC. S-1/A

As filed with the Securities and Exchange Commission on May 31, 2013 Registration No.

-

AEOLUS PHARMACEUTICALS, INC. May 31, 2013 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler Re: Aeolus Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed May 16, 2013 File No. 333-188670 Responses to United States Securities and Exchange Commission Staff (“Staff”) comments made by le

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - AEOLUS 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2013 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commission

Registration Statement - AEOLUS PHARMACEUTICALS, INC. S-1

As filed with the Securities and Exchange Commission on May 16, 2013 Registration No.

PROSPECTUS SUPPLEMENT NO. 5 DATED May 16, 2013 (To Prospectus Dated March 13, 2013)

Prospectus Supplement Filed Pursuant to Rule 424(b)(3) Registration No. 333-181409 PROSPECTUS SUPPLEMENT NO. 5 DATED May 16, 2013 (To Prospectus Dated March 13, 2013) This Prospectus Supplement No. 5, dated May 16, 2013 (“Supplement No. 5”), filed by Aeolus Pharmaceuticals, Inc. (the “Company”), modifies and supplements certain information contained in the Company’s prospectus, dated March 13, 201

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 ____________ FORM 10-K/A (Amendment No. 1) ____________ (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-K/A (Amendment No. 1) (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-504

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2013 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commission

AOLS / Aeolus Pharmaceuticals, Inc. / Xmark Opportunity Partners, LLC - AMENDMENT NO. 20 Activist Investment

THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 20)* Under the Securities Exchange Act of 1934 Aeolus Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.01 par value per share (Title of Class of Securities) 00765G109 (CUSIP Number) with copy to: Xmark Opportunity Partners, LLC Lowenstein Sandler LLP 90 Grove Street, Suite 201 1251 Avenue

***** AEOLUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except per share data)

EX-99.2 7 exh992.htm EXHIBIT 99.2 Exhibit 99.2 Contact: Russell Skibsted Sr. Vice President and Chief Financial Officer Aeolus Pharmaceuticals, Inc. 1-(949) 481-9825 AEOLUS PHARMACEUTICALS ANNOUNCES FIRST QUARTER FISCAL YEAR 2013 FINANCIAL RESULTS · Beginning Third Year of $118.4 Million BARDA Advance Research and Development Contract · Balance Sheet Strengthened With $3,225,000 Financing · Net Ca

PROSPECTUS SUPPLEMENT NO. 4 DATED March 13, 2013 (To Prospectus Dated March 13, 2013)

Prospectus Supplement Filed Pursuant to Rule 424(b)(3) Registration No. 333-181409 PROSPECTUS SUPPLEMENT NO. 4 DATED March 13, 2013 (To Prospectus Dated March 13, 2013) This Prospectus Supplement No. 4, dated March 13, 2013 (“Supplement No. 4”), filed by Aeolus Pharmaceuticals, Inc. (the “Company”), modifies and supplements certain information contained in the Company’s prospectus, dated March 13,

PROSPECTUS SUPPLEMENT NO. 2 DATED March 13, 2013 (To Prospectus Dated March 13, 2013)

Prospectus Supplement Filed Pursuant to Rule 424(b)(3) Registration No. 333-181409 PROSPECTUS SUPPLEMENT NO. 2 DATED March 13, 2013 (To Prospectus Dated March 13, 2013) This Prospectus Supplement No. 2, dated March 13, 2013 (“Supplement No. 2”), filed by Aeolus Pharmaceuticals, Inc. (the “Company”), modifies and supplements certain information contained in the Company’s prospectus, dated March 13,

PROSPECTUS SUPPLEMENT NO. 3 DATED March 13, 2013 (To Prospectus Dated March 13, 2013)

Prospectus Supplement Filed Pursuant to Rule 424(b)(3) Registration No. 333-181409 PROSPECTUS SUPPLEMENT NO. 3 DATED March 13, 2013 (To Prospectus Dated March 13, 2013) This Prospectus Supplement No. 3, dated March 13, 2013 (“Supplement No. 3”), filed by Aeolus Pharmaceuticals, Inc. (the “Company”), modifies and supplements certain information contained in the Company’s prospectus, dated March 13,

88,714,577 Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-181409 PROSPECTUS 88,714,577 Common Stock This prospectus relates to the offer and sale from time to time of up to 88,714,577 shares of our common stock, par value $0.01 per share, including an aggregate of 60,800,125 shares of common stock issuable upon exercise of warrants, which are held by the selling stockholders identified in this prospec

AEOLUS PHARMACEUTICALS, INC. COMMON STOCK WARRANT

EX-10.3 4 exh103.htm EXHIBIT 10.3 Exhibit 10.3 NEITHER THIS WARRANT NOR ANY OF THE SECURITIES ISSUABLE HEREUNDER HAVE BEEN REGISTERED UNDER THE SECURITIES ACT (AS DEFINED BELOW), OR APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT, OR (B) AN OPIN

Russell Skibsted

Exhibit 99.1 Contact: Russell Skibsted Sr. Vice President and Chief Financial Officer Aeolus Pharmaceuticals, Inc. 1-(949) 481-9825 AEOLUS PHARMACEUTICALS ANNOUNCES $3.2 MILLION PRIVATE PLACEMENT FINANCING Mission Viejo, CA, February 19, 2013- Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of novel compounds to pr

PROSPECTUS SUPPLEMENT NO. 1 DATED March 13, 2013 (To Prospectus Dated March 13, 2013)

Prospectus Supplement Filed Pursuant to Rule 424(b)(3) Registration No. 333-181409 PROSPECTUS SUPPLEMENT NO. 1 DATED March 13, 2013 (To Prospectus Dated March 13, 2013) This Prospectus Supplement No. 1, dated March 13, 2013 (“Supplement No. 1”), filed by Aeolus Pharmaceuticals, Inc. (the “Company”), modifies and supplements certain information contained in the Company’s prospectus, dated March 13,

AEOLUS PHARAMACEUTICALS, INC.

Exhibit 10.1 AEOLUS PHARAMACEUTICALS, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 19, 2013, between Aeolus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the purchasers identified on the signature pages hereto (each, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and c

AEOLUS PHARMACEUTICALS, INC.

EX-10.1 2 exh101.htm EXHIBIT 10.1 Exhibit 10.1 AEOLUS PHARMACEUTICALS, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 4, 2013, between Aeolus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the purchasers identified on the signature pages hereto (each, a “Purchaser” and collectively, the “Purchasers”). WHEREA

AEOLUS PHARAMACEUTICALS, INC. REGISTRATION RIGHTS AGREEMENT

Exhibit 10.2 AEOLUS PHARAMACEUTICALS, INC. REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (the “Agreement”) is made and entered into as of March 4, 2013 by and among Aeolus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the “Purchasers” named in that certain Securities Purchase Agreement by and among the Company and the Purchasers, dated as of an even date her

AEOLUS PHARAMACEUTICALS, INC. REGISTRATION RIGHTS AGREEMENT

EX-10.2 3 exh102.htm EXHIBIT 10.2 Exhibit 10.2 AEOLUS PHARAMACEUTICALS, INC. REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (the “Agreement”) is made and entered into as of February 19, 2013 by and among Aeolus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the “Purchasers” named in that certain Securities Purchase Agreement by and among the Company and the Pu

AEOLUS PHARMACEUTICALS, INC. COMMON STOCK WARRANT

Exhibit 10.3 NEITHER THIS WARRANT NOR ANY OF THE SECURITIES ISSUABLE HEREUNDER HAVE BEEN REGISTERED UNDER THE SECURITIES ACT (AS DEFINED BELOW), OR APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT, OR (B) AN OPINION OF COUNSEL, IN A GENERALLY ACC

WARRANT REPRICING, EXERCISE AND LOCKUP AGREEMENT

EX-10.4 5 exh104.htm EXHIBIT 10.4 Exhibit 10.4 WARRANT REPRICING, EXERCISE AND LOCKUP AGREEMENT This Warrant Repricing, Exercise and Lockup Agreement (this “Agreement”) is made as of February 19, 2013, by and among Aeolus Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and each of the persons listed on the Schedule of Warrant Holders attached hereto as Exhibit A (the “Holders”). RECI

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of March 4, 2013, by and between Aeolus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and John L. McManus (“Executive”). RECITALS A. Executive has been President and Chief Executive Officer (“CEO”) of the Company since 2006, and was r

-

Aeolus Pharmaceuticals, Inc. 26361 Crown Valley Parkway, Suite 150 Mission Viejo, California 92691 March 8, 2013 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Jeffrey Riedler Re: Aeolus Pharmaceuticals, Inc. Post-Effective Amendment No. 1 to Form S-1 Filed February 20, 2013 File No. 333-181409 Request for Accel

AEOLUS PHARMACEUTICALS, INC.

EX-10.1 2 exh101.htm EXHIBIT 10.1 Exhibit 10.1 AEOLUS PHARMACEUTICALS, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 4, 2013, between Aeolus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the purchasers identified on the signature pages hereto (each, a “Purchaser” and collectively, the “Purchasers”). WHEREA

AEOLUS PHARAMACEUTICALS, INC. REGISTRATION RIGHTS AGREEMENT

EX-10.2 3 exh102.htm EXHIBIT 10.2 Exhibit 10.2 AEOLUS PHARAMACEUTICALS, INC. REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (the “Agreement”) is made and entered into as of March 4, 2013 by and among Aeolus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the “Purchasers” named in that certain Securities Purchase Agreement by and among the Company and the Purcha

AEOLUS PHARMACEUTICALS, INC. COMMON STOCK WARRANT

EX-10.3 4 exh103.htm EXHIBIT 10.3 Exhibit 10.3 NEITHER THIS WARRANT NOR ANY OF THE SECURITIES ISSUABLE HEREUNDER HAVE BEEN REGISTERED UNDER THE SECURITIES ACT (AS DEFINED BELOW), OR APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT, OR (B) AN OPIN

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - AEOLUS PHARMACEUTICALS, INC. 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2013 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commissio

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2013 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commissio

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of March 4, 2013, by and between Aeolus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and John L. McManus (“Executive”). RECITALS A. Executive has been President and Chief Executive Officer (“CEO”) of the Company since 2006, and was r

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated March 1, 2013 with respect to the shares of Common Stock of Aeolus Pharmaceuticals, Inc., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the S

AOLS / Aeolus Pharmaceuticals, Inc. / BIOTECHNOLOGY VALUE FUND L P Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Aeolus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 00765G109 (CUSIP Numbe

- AEOLUS PHARMACEUTICALS, INC. POS AM

As filed with the Securities and Exchange Commission on February 20, 2013 Registration No.

- AEOLUS POS AM

As filed with the Securities and Exchange Commission on February 19, 2013 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2012.

WARRANT REPRICING, EXERCISE AND LOCKUP AGREEMENT

EX-10.4 5 exh104.htm EXHIBIT 10.4 Exhibit 10.4 WARRANT REPRICING, EXERCISE AND LOCKUP AGREEMENT This Warrant Repricing, Exercise and Lockup Agreement (this “Agreement”) is made as of February 19, 2013, by and among Aeolus Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and each of the persons listed on the Schedule of Warrant Holders attached hereto as Exhibit A (the “Holders”). RECI

Russell Skibsted

Exhibit 99.1 Contact: Russell Skibsted Sr. Vice President and Chief Financial Officer Aeolus Pharmaceuticals, Inc. 1-(949) 481-9825 AEOLUS PHARMACEUTICALS ANNOUNCES $3.2 MILLION PRIVATE PLACEMENT FINANCING Mission Viejo, CA, February 19, 2013- Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of novel compounds to pr

AEOLUS PHARAMACEUTICALS, INC. REGISTRATION RIGHTS AGREEMENT

Exhibit 10.2 AEOLUS PHARAMACEUTICALS, INC. REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (the “Agreement”) is made and entered into as of February 19, 2013 by and among Aeolus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the “Purchasers” named in that certain Securities Purchase Agreement by and among the Company and the Purchasers, dated as of an even date

Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Results of Operations and Financial Condition, Other Events - AEOLUS PHARMACEUTICALS, INC. 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2013 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commi

AEOLUS PHARMACEUTICALS, INC. COMMON STOCK WARRANT

Exhibit 10.3 NEITHER THIS WARRANT NOR ANY OF THE SECURITIES ISSUABLE HEREUNDER HAVE BEEN REGISTERED UNDER THE SECURITIES ACT (AS DEFINED BELOW), OR APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT, OR (B) AN OPINION OF COUNSEL, IN A GENERALLY ACC

***** AEOLUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except per share data)

Exhibit 99.2 Contact: Russell Skibsted Sr. Vice President and Chief Financial Officer Aeolus Pharmaceuticals, Inc. 1-(949) 481-9825 AEOLUS PHARMACEUTICALS ANNOUNCES FIRST QUARTER FISCAL YEAR 2013 FINANCIAL RESULTS · Beginning Third Year of $118.4 Million BARDA Advance Research and Development Contract · Balance Sheet Strengthened With $3,225,000 Financing · Net Cash Used In Operations Reduced To O

AEOLUS PHARAMACEUTICALS, INC.

EX-10.1 2 exh101.htm EXHIBIT 10.1 Exhibit 10.1 AEOLUS PHARAMACEUTICALS, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 19, 2013, between Aeolus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the purchasers identified on the signature pages hereto (each, a “Purchaser” and collectively, the “Purchasers”). W

- AEOLUS PHARMACEUTICALS, INC. NT 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-50481 NOTIFICATION OF LATE FILING CUSIP NUMBER 00765G109 (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2012 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Tra

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION AEOLUS PHARMACEUTICALS, INC.

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AEOLUS PHARMACEUTICALS, INC. Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware (the ?DGCL?), the undersigned corporation hereby submits the following for the purpose of amending and restating its Certificate of Incorporation, and does hereby certify as follows: 1. The name of the corporation is

LIST OF SUBSIDIARIES

EXHIBIT 21.1 LIST OF SUBSIDIARIES Aeolus Sciences, Inc., a Delaware corporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-K (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-50481 AEOLUS PHARMACEUT

- AEOLUS PHARMACEUTICALS, INC. SCHEDULE 14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: o Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement Aeolus Pharmaceutic

-

1(650) 320-1804 [email protected] November 13, 2012 77251.00001 VIA EDGAR (“CORRESP”) United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Johnny Gharib Re: Aeolus Pharmaceuticals, Inc. Information Statement on Schedule 14C Filed on November 6, 2012 File No. 000-50481 Dear Mr. Gharib: On behalf of Aeolu

- AEOLUS PHARMACEUTICALS PRER14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: x Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) o Definitive Information Statement Aeolus Pharmaceutic

- AEOLUS PHARMACEUTICALS, INC. PRE 14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: x Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) o Definitive Information Statement Aeolus Pharmaceutic

Appendix 2 to the Research and Manufacturing Agreement Johnson Matthey Pharma Services and Aeolus Pharmaceuticals Dated: February 16, 2011 Proposal #: AEO-110902-972 Title: Impurity Isolation and Process Research and Development for AEOL Preparation

Exhibit 10.4 *** Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2 Appendix 2 to the Research and Manufacturing Agreement Between Johnson Matthey Pharma Services and Aeolus Pharmaceuticals Dated: February 16, 2011 Proposal #: AEO-110902-972 Title: Impurity Isolation and Process Research and Development for AEOL 10150 Preparation Date:

Prospectus Supplement Filed Pursuant to Rule 424(b)(3) Registration No. 333-181409 PROSPECTUS SUPPLEMENT NO. 1 DATED August 17, 2012 (To Prospectus Dated May 29, 2012) This Prospectus Supplement No. 1, dated August 17, 2012 (“Supplement No. 1”), file

Prospectus Supplement Filed Pursuant to Rule 424(b)(3) Registration No. 333-181409 PROSPECTUS SUPPLEMENT NO. 1 DATED August 17, 2012 (To Prospectus Dated May 29, 2012) This Prospectus Supplement No. 1, dated August 17, 2012 (“Supplement No. 1”), filed by Aeolus Pharmaceuticals, Inc. (the “Company”), modifies and supplements certain information contained in the Company’s prospectus, dated May 29, 2

Stage #

Exhibit 10.6 March, 28 2012 Stephanie McSwain Vice President, Manufacturing Aeolus Pharmaceuticals, Inc. 26361 Crown Valley Parkway Mission Viejo, CA 92681 Dear Stephanie, Thank you for your continued interest in Johnson Matthey Pharma Services (JMPS). As a follow-up to your recent request, we are pleased to provide Aeolus Pharmaceuticals (Aeolus) with this proposal for Scale-up Development and cG

Est. Direct Expenses*

Exhibit 10.5 March, 28 2012 Stephanie McSwain Vice President, Manufacturing Aeolus Pharmaceuticals, Inc. 26361 Crown Valley Parkway Mission Viejo, CA 92681 Dear Stephanie, Thank you for your continued interest in Johnson Matthey Pharma Services (JMPS). As a follow-up to your recent request, we are pleased to provide Aeolus Pharmaceuticals (Aeolus) with this proposal for Solid Form Screening and Ch

Service Fee*

Exhibit 10.8 March, 28 2012 Stephanie McSwain Vice President, Manufacturing Aeolus Pharmaceuticals, Inc. 26361 Crown Valley Parkway Mission Viejo, CA 92681 Dear Stephanie, Thank you for your continued interest in Johnson Matthey Pharma Services (JMPS). As a follow-up to your recent request, we are pleased to provide Aeolus Pharmaceuticals (Aeolus) with this proposal for Aldehyde Development and no

Service Fee

Exhibit 10.7 March, 28 2012 Stephanie McSwain Vice President, Manufacturing Aeolus Pharmaceuticals, Inc. 26361 Crown Valley Parkway Mission Viejo, CA 92681 Dear Stephanie, Thank you for your continued interest in Johnson Matthey Pharma Services (JMPS). As a follow-up to your recent request, we are pleased to provide Aeolus Pharmaceuticals (Aeolus) with this proposal for Program Support, Process De

Service Fee*

Exhibit 10.8 March, 28 2012 Stephanie McSwain Vice President, Manufacturing Aeolus Pharmaceuticals, Inc. 26361 Crown Valley Parkway Mission Viejo, CA 92681 Dear Stephanie, Thank you for your continued interest in Johnson Matthey Pharma Services (JMPS). As a follow-up to your recent request, we are pleased to provide Aeolus Pharmaceuticals (Aeolus) with this proposal for Aldehyde Development and no

Est. Direct Expenses*

EX-10.5 3 exh105.htm EXHIBIT 10.5 Exhibit 10.5 March, 28 2012 Stephanie McSwain Vice President, Manufacturing Aeolus Pharmaceuticals, Inc. 26361 Crown Valley Parkway Mission Viejo, CA 92681 Dear Stephanie, Thank you for your continued interest in Johnson Matthey Pharma Services (JMPS). As a follow-up to your recent request, we are pleased to provide Aeolus Pharmaceuticals (Aeolus) with this propos

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012.

Stage #

Exhibit 10.6 March, 28 2012 Stephanie McSwain Vice President, Manufacturing Aeolus Pharmaceuticals, Inc. 26361 Crown Valley Parkway Mission Viejo, CA 92681 Dear Stephanie, Thank you for your continued interest in Johnson Matthey Pharma Services (JMPS). As a follow-up to your recent request, we are pleased to provide Aeolus Pharmaceuticals (Aeolus) with this proposal for Scale-up Development and cG

Appendix 2 to the Research and Manufacturing Agreement Johnson Matthey Pharma Services and Aeolus Pharmaceuticals Dated: February 16, 2011 Proposal #: AEO-110902-972 Title: Impurity Isolation and Process Research and Development for AEOL Preparation

Exhibit 10.4 *** Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. ?? 200.80(b)(4) and 240.24b-2 Appendix 2 to the Research and Manufacturing Agreement Between Johnson Matthey Pharma Services and Aeolus Pharmaceuticals Dated: February 16, 2011 Proposal #: AEO-110902-972 Title: Impurity Isolation and Process Research and Development for AEOL 10150 Preparation Date:

Service Fee

Exhibit 10.7 March, 28 2012 Stephanie McSwain Vice President, Manufacturing Aeolus Pharmaceuticals, Inc. 26361 Crown Valley Parkway Mission Viejo, CA 92681 Dear Stephanie, Thank you for your continued interest in Johnson Matthey Pharma Services (JMPS). As a follow-up to your recent request, we are pleased to provide Aeolus Pharmaceuticals (Aeolus) with this proposal for Program Support, Process De

88,714,577 Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-181409 PROSPECTUS 88,714,577 Common Stock This prospectus relates to the offer and sale from time to time of up to 88,714,577 shares of our common stock, par value $0.01 per share, including an aggregate of 60,800,125 shares of common stock issuable upon exercise of warrants, which are held by the selling stockholders identified in this prospec

- AEOLUS PHARMACEUTICALS S-1/A

As filed with the Securities and Exchange Commission on May 17, 2012 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012.

Registration Statement - AEOLUS PHARMACEUTICALS S-1

As filed with the Securities and Exchange Commission on May 14, 2012 Registration No.

Entry into a Material Definitive Agreement - AEOLUS PHARMACEUTICALS 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2012 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commissi

AOLS / Aeolus Pharmaceuticals, Inc. / Efficacy Capital, Ltd. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 4)* Under the Securities Exchange Act of 1934 Aeolus Pharmaceuticals, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 00765G109 (CUSIP Number) EFFICACY CAPITAL LTD. with a copy to: Mintz Levin Cohn Ferris Glovsky and Popeo PC Mark Lappe, Managing Partner Jeremy D. Glaser, Esq. 11

Regulation FD Disclosure, Financial Statements and Exhibits - AEOLUS PHARMACEUTICALS 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 09, 2012 (Date of earliest event reported) Aeolus Pharmaceuticals (Exact name of registrant as specified in its charter) CA (State or other jurisdiction of incorporation) 000-50481 (Commission File Number) 56-19

MISSION VIEJO, CA -- (Marketwire - April 09, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS)

BARDA Delivers Notice of Intent to Exercise Additional Contract Options With Aeolus Worth $9.

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - AEOLUS PHARMACEUTICALS 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 30, 2012 AEOLUS PHARMACEUTICALS (Exact name of registrant as specified in its charter) Delaware 0-50481 56-1953785 (State or other jurisdiction of incorporation or organization)

AEOLUS PHARMACEUTICALS, INC. COMMON STOCK WARRANT

EX-10.3 4 exh103.htm EXHIBIT 10.3 Exhibit 10.3 NEITHER THIS WARRANT NOR ANY OF THE SECURITIES ISSUABLE HEREUNDER HAVE BEEN REGISTERED UNDER THE SECURITIES ACT (AS DEFINED BELOW), OR APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT, OR (B) AN OPIN

AEOLUS PHARAMACEUTICALS, INC.

EX-10.1 2 exh101.htm EXHIBIT 10.1 Exhibit 10.1 AEOLUS PHARAMACEUTICALS, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2012, between Aeolus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the purchasers identified on the signature pages hereto (each, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, sub

AEOLUS PHARAMACEUTICALS, INC. REGISTRATION RIGHTS AGREEMENT

Exhibit 10.2 AEOLUS PHARAMACEUTICALS, INC. REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (the “Agreement”) is made and entered into as of , 2012 by and among Aeolus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the “Purchasers” named in that certain Securities Purchase Agreement by and among the Company and the Purchasers, dated as of an even date herewith (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2011.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-K/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-K/A (Amendment No. 1) (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-504

AEOLUS PHARMACEUTICALS, INC. INDEMNITY AGREEMENT

EXHIBIT 10.27 AEOLUS PHARMACEUTICALS, INC. INDEMNITY AGREEMENT This Indemnity Agreement (this ?Agreement?) is made and entered into as of [], 20[], by and between Aeolus Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and [Name of Director/Officer] (?Agent?). Recitals WHEREAS, Agent performs a valuable service to the Company in his capacity as [Officer title(s)][a Director] of the C

LIST OF SUBSIDIARIES

EXHIBIT 21.1 LIST OF SUBSIDIARIES Aeolus Sciences, Inc., a Delaware corporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-K (MARK ONE) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-50481 AEOLUS PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A Amendment No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2011 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-50481 56-1953785 (State or other jurisdiction (Commission (IRS Employer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011.

Aeolus Pharmaceuticals Announces Third Quarter Fiscal Year 2011 Results

EX-99.1 2 v232110ex99-1.htm EX-99.1 Contact: Russell Skibsted (949) 481-9825 Aeolus Pharmaceuticals Announces Third Quarter Fiscal Year 2011 Results · Significant Progress in BARDA Base Contract Deliverables Accomplished During Quarter Mission Viejo, California, August 15, 2011 — Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) announced today financial results for the three months ended June 30, 2011.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2011 AEOLUS PHARMACEUTICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2011 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commission

July 7, 2011

Exhibit 16.1 July 7, 2011 U.S. Securities and Exchange Commission Office of the Chief Accountant 100 F Street, N.E. Washington, DC 20549-7561 Dear Sir or Madam: We have been furnished with a copy of and read the disclosure contained in Item 4.01, “Changes in Registrant’s Certifying Accountant,” of Aeolus Pharmaceuticals, Inc.’s Current Report on Form 8-K dated July 6, 2011. We agree with the state

Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this proposal.

Exhibit 10.3 *** Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. ?? 200.80(b)(4) and 240.24b-2 Aeolus Pharmaceuticals: Proposed Evaluation and Operational Support in Quality Assurance, Program Management, and Document Management February 23, 2011 The data contained in all pages of this proposal have been submitted in confidence and contain trade secrets and/or pr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2011.

Subaward Agreement

EX-10.4 15 v221918ex10-4.htm Exhibit 10.4 *** Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2 Subaward Agreement Institution/Organization ("Company") Institution/Organization ("UMB") Name: Aeolus Pharmaceuticals, Inc. Name: University of Maryland, Baltimore Address: 26361 Crown Valley Parkway, Suite 150 Address: Office of Research an

* * * * * * * * * *

1(650) 320-1804 [email protected] May 16, 2011 Via EDGAR (“Corresp”) and Overnight Mail United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Jim B. Rosenberg Re: Aeolus Pharmaceuticals, Inc. Form 10-K for the Year Ended September 30, 2010 Definitive Information Statement filed January 26, 2011 Form 8-K

RESEARCH AND MANUFACTURING AGREEMENT

Exhibit 10.2 *** Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2 RESEARCH AND MANUFACTURING AGREEMENT This Agreement is made and entered into as of the 16th day of February, 2011 (the “Effective Date”) by and between Aeolus Pharmaceuticals, Inc., a Delaware corporation, having a principal place of business at 26361 Crown Valley Parkw

Exclusive License Agreement National Jewish Health and Aeolus Pharmaceuticals, Inc.

Exhibit 10.7 Exclusive License Agreement between National Jewish Health and Aeolus Pharmaceuticals, Inc. This Exclusive License Agreement (?Agreement?) is effective as of January 15, 2009 (the ?Effective Date?) by and between National Jewish Health (?National Jewish?), having an address at 1400 Jackson Street, Denver, Colorado 80206, and Aeolus Pharmaceuticals, Inc. (?Aeolus?), having an address a

PAGE OF PAGES

EX-10.1 2 v221918ex10-1.htm Exhibit 10.1 *** Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2 OMB Approval 0990-0115 1.THIS CONTRACT IS A RATED ORDER RATING PAGE OF PAGES AWARD/CONTRACT UNDER DPAS (15 CFR 350) Ø N/A 1 43 2. CONTRACT (Proc. Inst. Ident.) NO. 3. EFFECTIVE DATE 4. REQUISITION/PURCHASE REQUEST/PROJECT NO. HHSO100201100007

SPONSORED RESEARCH AGREEMENT (NON-CLINICAL)

Exhibit 10.5 *** Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. ?? 200.80(b)(4) and 240.24b-2 SPONSORED RESEARCH AGREEMENT (NON-CLINICAL) This agreement (?AGREEMENT?) is between DUKE UNIVERSITY (?DUKE?), a North Carolina non-profit corporation, located in Durham, North Carolina, and AEOLUS PHARMACEUTICALS, INC. (?AEOLUS?), a Delaware Corporation having offices a

As filed with the Securities and Exchange Commission on April 28, 2011 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Aeolus Pharmaceuticals, Inc. (Exact name of regi

Registration No. 333- As filed with the Securities and Exchange Commission on April 28, 2011 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aeolus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 56-1953785 (State or other jurisdiction of (I.R.S. Employer incorporation or

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2011 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commissi

[Aeolus Pharmaceuticals, Inc. Letterhead]

[Aeolus Pharmaceuticals, Inc. Letterhead] April 4, 2011 Via EDGAR (“Corresp”) and Overnight Mail United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Jim B. Rosenberg Re: Aeolus Pharmaceuticals, Inc. Form 10-K for the Year Ended September 30, 2010 Definitive Information Statement filed January 26, 2011 Form 8-K fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 02 )* AEOLUS PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 45325 S-10-1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 02 )* AEOLUS PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 45325 S-10-1 (CUSIP Number) MARK LAPPE, MANAGING PARTNER, EFFICACY CAPITAL, LTD. 11622 EL CAMINO REAL, SUITE 100 SAN DIEGO, CALIFORNIA 92130 Phone : (858) 759-149

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2011 AEOLUS PHARMACEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2011 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2011 AEOLUS PHARMACE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2011 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commi

POWER OF ATTORNEY

Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints John L.

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 19)* Under the Securities Exchange Act of 1934 Aeolus Pharmaceuticals, Inc. (Name of Issuer) Common stock, $.01 par value per share (Title of Class of Securities) 00765G109 (CUSIP Number) with copy to: Xmark Opportunity Partners, LLC Lowenstein Sandler PC 90 Grove Street, Suite 201 1251 Avenue of th

2

Exhibit 99.1 Contact: Russell Skibsted Sr. Vice President and Chief Financial Officer Aeolus Pharmaceuticals, Inc. (949) 481-9825 AEOLUS PHARMACEUTICALS ANNOUNCES APPOINTMENT OF RUSSELL L. SKIBSTED AS SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER MISSION VIEJO, California ? February 15, 2011? Aeolus Pharmaceuticals, Inc. (OTC: AOLS), a biopharmaceutical company developing a new class of broad

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2011 AEOLUS PHARMACE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2011 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commi

-2-

Exhibit 10.1 September 1, 2010 Russell Skibsted 15 Tranquility Place Ladera Ranch, CA 92694 Dear Russ: This letter confirms our previous conversations regarding the employment opportunity available to you with Aeolus Pharmaceuticals, Inc. (the “Company”) and sets forth the terms and conditions of that employment. The Company hereby offers you full-time employment as Senior Vice President, Chief Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2011 AEOLUS PHARMACE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2011 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commi

AEOLUS AWARDED CONTRACT FULLY VALUED AT $118 MILLION FROM BARDA TO DEVELOP TREATMENT FOR LUNG ACUTE RADIATION SYNDROME

99.1 Contact: Russell Skibsted Sr. Vice President and Chief Financial Officer Aeolus Pharmaceuticals, Inc.(949) 481-9825 AEOLUS AWARDED CONTRACT FULLY VALUED AT $118 MILLION FROM BARDA TO DEVELOP TREATMENT FOR LUNG ACUTE RADIATION SYNDROME ? Contract, with options, valued at up to $118 million over 5 years ? Funding would bring AEOL 10150 from its current stage of development to FDA approval ? Saf

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2010.

CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AEOLUS PHARMACEUTICALS, INC.

EXHIBIT 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AEOLUS PHARMACEUTICALS, INC. AEOLUS PHARMACEUTICALS, INC., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: FIRST: The name of the Corporation is AEOLUS PHARMACEUTICALS, INC. (the “Corporation”). The date on

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2011 AEOLUS PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2011 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ______)

DEF 14C 1 v208784def14c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: ¨ Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Information S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2010 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-50

List of Subsidiaries

Exhibit 21.1 List of Subsidiaries Aeolus Sciences, Inc., a Delaware corporation.

List of Subsidiaries

Exhibit 21.1 List of Subsidiaries Aeolus Sciences, Inc., a Delaware corporation.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2010 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-50481 AEOLUS PHARMACEU

Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2010 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2010 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commis

CONSULTING AGREEMENT

Exhibit 10.1 CONSULTING AGREEMENT This agreement (?Agreement?) made as of this 1st day of December 2010 by and between Aeolus Pharmaceuticals, Inc. and its subsidiary, Aeolus Sciences, Inc., both Delaware corporations (hereinafter collectively referred to as the ?Company?) and Brian J. Day (the ?Consultant?) of 6122 South Nome Ct., Englewood, CO 80111. The Company is engaged in research and develo

PROSPECTUS 24,767,039 Shares of Common Stock

Prospectus Supplement filed pursuant to Rule 424(b)(3) Registration No. 333-135541 PROSPECTUS 24,767,039 Shares of Common Stock We are registering our common stock, par value $0.01 per share, for resale by the selling stockholders identified in this prospectus. The selling stockholders or their permitted transferees or other successors in interest may, but are not required to, sell their common st

As filed with the Securities and Exchange Commission on September 28, 2010 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aeolus

Registration No. 333-135541 As filed with the Securities and Exchange Commission on September 28, 2010 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aeolus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 56-1953785 (State or other jur

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 18)* Under the Securities Exchange Act of 1934 Aeolus Pharmaceuticals, Inc. (Name of Issuer) Common stock, $.01 par value per share (Title of Class of Securities) 00765G109 (CUSIP Number) with copy to: Xmark Opportunity Partners, LLC Lowenstein Sandler PC 90 Grove Street, Suite 201 1251 Avenue of th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2010.

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2010 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commiss

REGISTRATION RIGHTS AGREEMENT

REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of August 11, 2010, by and among Aeolus Pharmaceuticals, Inc.

SECURITIES PURCHASE AGREEMENT

EXECUTION VERSION SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of August 11, 2010, by and among Aeolus Pharmaceuticals, Inc.

FORM OF WARRANT

FORM OF WARRANT NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.

Aeolus Pharmaceuticals Completes $1.0 Million Financing and Receives an Option to Raise Additional $1.0 Million

Contact: John L. McManus President and Chief Executive Officer Aeolus Pharmaceuticals, Inc. 1-(949) 481-9825 Aeolus Pharmaceuticals Completes $1.0 Million Financing and Receives an Option to Raise Additional $1.0 Million MISSION VIEJO, CA— August 12, 2010 — Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS; “Aeolus Pharmaceuticals” or the “Company”) announced today that it has completed a $1.

Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2010 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commissio

EX-10.4

v192095ex10-4 - Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010.

Aeolus Pharmaceuticals, Inc. Prospectus Supplement No. 2 dated March 25, 2010 (To Prospectus dated July 19, 2007, as supplemented by Prospectus Supplement No. 1 dated November 7, 2007) 4,853,335 shares of common stock

Prospectus Supplement filed pursuant to Rule 424(b)(3) in connection with Registration Statement No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2009.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-50481 NOTIFICATION OF LATE FILING CUSIP NUMBER 00765G109 (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2009 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Tra

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response 10.4 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* AEOLUS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00765G109 (CUSIP Number) December 31, 2009 (Date of

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 6)1 Aeolus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 00765G109 (CUSIP Numb

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G dated February 3, 2010 with respect to the shares of Common Stock of Aeolus Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ______)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: ¨ Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement Aeolus Pharmaceutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2010 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commis

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2009 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2009 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-50481 AEOLUS PHARMACEU

Aeolus Pharmaceuticals Announces Fiscal Year 2009 Financial Results

Exhibit 99.1 Contact: John L. McManus President and Chief Executive Officer (949) 481-9825 Aeolus Pharmaceuticals Announces Fiscal Year 2009 Financial Results Mission Viejo, California, December 28, 2009 - Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) announced today financial results for the three months and twelve months ended September 30, 2009. The Company reported a net loss of $746

As filed with the Securities and Exchange Commission on December 28, 2009

As filed with the Securities and Exchange Commission on December 28, 2009 Registration No.

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2009 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commi

List of Subsidiaries

Exhibit 21.1 List of Subsidiaries Aeolus Sciences, Inc., a Delaware corporation.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 24, 2009 AEOLUS PHARMACE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 24, 2009 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commi

As filed with the Securities and Exchange Commission on December 28, 2009

As filed with the Securities and Exchange Commission on December 28, 2009 Registration No.

AMENDMENT AGREEMENT TO THE SECURITIES PURCHASE AND EXCHANGE AGREEMENT

Exhibit 10.1 AMENDMENT AGREEMENT TO THE SECURITIES PURCHASE AND EXCHANGE AGREEMENT THIS AMENDMENT AGREEMENT TO THE SECURITIES PURCHASE AND EXCHANGE AGREEMENT (this "Amendment Agreement"), dated as of December 24, 2009 (the "Effective Date"), is made and entered into by and among Aeolus Pharmaceuticals, Inc. (the "Company"), Xmark Opportunity Fund, L.P. ("XLP"), Xmark Opportunity Fund, Ltd. ("XLTD"

As filed with the Securities and Exchange Commission on December 28, 2009

As filed with the Securities and Exchange Commission on December 28, 2009 Registration No.

REGISTRATION RIGHTS AGREEMENT

EX-4.1 2 ex41rra.htm REGISTRATION RIGHTS AGREEMENT DATED OCTOBER 6, 2009 BY AND AMONG THE COMPANY AND THE INVESTORS WHOSE NAMES APPEAR ON THE SIGNATURE PAGES THEREOF Exhibit 4.1 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 6, 2009, by and among Aeolus Pharmaceuticals, Inc., a Delaware corporation, with headquarters located at 26361 Crown Valle

Aeolus Pharmaceuticals Completes $1.65 Million Financing, Converts $1 Million in Debt to Common Stock and Receives an Option to Raise Additional $1.65 Million

EX-99.1 5 ex991pressrelease.htm PRESS RELEASE DATED OCTOBER 6, 2009 Contact: John L. McManus. President and Chief Executive Officer Aeolus Pharmaceuticals, Inc. 1-(949) 481-9825 Aeolus Pharmaceuticals Completes $1.65 Million Financing, Converts $1 Million in Debt to Common Stock and Receives an Option to Raise Additional $1.65 Million MISSION VIEJO, CA— October 6, 2009 - Aeolus Pharmaceuticals, In

SECURITIES PURCHASE AND EXCHANGE AGREEMENT

EX-10.1 3 ex101spec.htm SECURITIES PURCHASE AND EXCHANGE AGREEMENT DATED OCTOBER 6, 2009 BY AND AMONG THE COMPANY AND THE INVESTORS WHOSE NAMES APPEAR ON THE SIGNATURE PAGES THEREOF Exhibit 10.1 SECURITIES PURCHASE AND EXCHANGE AGREEMENT SECURITIES PURCHASE AND EXCHANGE AGREEMENT (this “Agreement”), dated as of October 6, 2009, by and among Aeolus Pharmaceuticals, Inc., a Delaware corporation with

FORM OF WARRANT

EX-10.2 4 ex102warrant.htm FORM OF WARRANT TO PURCHASE COMMON STOCK Exhibit 10.2 FORM OF WARRANT NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSF

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2009 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481  0; 56-1953785 (Co

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2009 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commissio

Aeolus Pharmaceuticals Announces Third Quarter Fiscal Year 2009 Financial Results

EX-99.1 2 pressrelease3rdqtr09.htm 3RD QTR 09 EARNINGS RELEASE DATED JULY 31, 2009 Exhibit 99.1 Contact: John L. McManus President and Chief Executive Officer (949) 481-9825 Aeolus Pharmaceuticals Announces Third Quarter Fiscal Year 2009 Financial Results Mission Viejo, California, July 31, 2009 - Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) announced today financial results for the thr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2009.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2009.

Aeolus Pharmaceuticals Announces Second Quarter Fiscal Year 2009 Financial Results

Exhibit 99.1 Contact: John L. McManus President and Chief Executive Officer (949) 481-9825 Aeolus Pharmaceuticals Announces Second Quarter Fiscal Year 2009 Financial Results Mission Viejo, California, May 1, 2009 - Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) announced today financial results for the three months ended March 31, 2009. The Company reported a net loss of $665,000, or $0.0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2009 AEOLUS PHARMACEUTICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2009 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commission

FORM OF WARRANT

EX-10.2 4 ex102.htm EXHIBIT 10.2 - FORM OF WARRANT Exhibit 10.2 FORM OF WARRANT NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED

Aeolus Pharmaceuticals Completes $1.5 Million Financing

Exhibit 99.1 Contact: John L. McManus. President and Chief Executive Officer Aeolus Pharmaceuticals, Inc. 1-(949) 481-9825 Aeolus Pharmaceuticals Completes $1.5 Million Financing MISSION VIEJO, CA—March 31, 2009 - Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) announced today that it completed a $1.5 million financing with two existing institutional shareholders, both of which are affilia

AMENDMENT NO. 2 TO SECURITIES PURCHASE AGREEMENT

Exhibit 10.3 AMENDMENT NO. 2 TO SECURITIES PURCHASE AGREEMENT This AMENDMENT NO. 2 TO SECURITIES PURCHASE AGREEMENT (this "Amendment"), is being entered into and effective as of March 30, 2009, by and among AEOLUS PHARMACEUTICALS, INC., a Delaware corporation with its headquarters located at 26361 Crown Valley Parkway, Suite 150, Mission Viejo, California 92691, as issuer (the "Company"), and XMAR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2009 AEOLUS PHARMACEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2009 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commissi

REGISTRATION RIGHTS AGREEMENT

Exhibit 4.1 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 30, 2009, by and among Aeolus Pharmaceuticals, Inc., a Delaware corporation, with headquarters located at 26361 Crown Valley Parkway, Suite 150, Mission Viejo, California 92691 (the “Company”), and the investors listed on the Schedule of Buyers attached hereto (each, a “Buyer” and collecti

SECURITIES PURCHASE AGREEMENT

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of March 30, 2009, by and among Aeolus Pharmaceuticals, Inc., a Delaware corporation with its headquarters located at 26361 Crown Valley Parkway, Suite 150, Mission Viejo, California 92691 (the ?Company?), and the investors listed on the Schedule of Buyers attached hereto (individually, a ?Buyer?

AMENDMENT NO. 1 TO CONVERTIBLE PROMISSORY NOTE

EX-10.1 2 ex101amndmt.htm AMEND NO 1 TO CONV PROMISSORY NOTE EXHIBIT 10.1 AMENDMENT NO. 1 TO CONVERTIBLE PROMISSORY NOTE This Amendment No. 1 to Convertible Promissory Note (this “Amendment”) is made and entered into as of February 7, 2009, by and between Aeolus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Elan Pharma International Limited, an Irish private limited liability

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2009 AEOLUS PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2009 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2008.

Aeolus Pharmaceuticals Announces First Quarter Fiscal Year 2009 Financial Results

Exhibit 99.1 Contact: John L. McManus President and Chief Executive Officer (949) 481-9825 Aeolus Pharmaceuticals Announces First Quarter Fiscal Year 2009 Financial Results Laguna Niguel, California, February 6, 2009 - Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS.OB) announced today financial results for the three months ended December 31, 2008. The Company reported a net loss of $459,00

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2009 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive

SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 5)* Aeolus Phar

SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No.

* * * * *

VIA EDGAR AND OVERNIGHT MAIL January 16, 2009 Mr. John L. Krug Senior Counsel Securities and Exchange Commission Division of Corporation Finance Mail Stop 0610 100 F Street, NE Washington, DC 20549 Re: Aeolus Pharmaceuticals, Inc. Preliminary Proxy Statement filed January 13, 2009 File Number 000-50481 Dear Mr. Krug: The following comments are in response to your letter dated January 15, 2009 to A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ý Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2008 ¨ TRANSITION REPORT PURSU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2008 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-50481 AEOLUS PHARMACEU

List of Subsidiaries

Exhibit 21.1 List of Subsidiaries Aeolus Sciences, Inc., a Delaware corporation.

Aeolus Pharmaceuticals Announces Fiscal Year 2008 Financial Results

Contact: John L. McManus President and Chief Executive Officer (949) 481-9825 Aeolus Pharmaceuticals Announces Fiscal Year 2008 Financial Results Mission Viejo, California, December 12, 2008 - Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) announced today financial results for the three months and twelve months ended September 30, 2008. The Company reported a net loss of $1,055,000, or $0

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2008 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481 56-1953785 (Commi

Other Events

8-K 1 form8k-bodcomp.htm FORM 8-K DATED DECEMBER 11, 2008 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2008 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or othe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2008.

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2008 AEOLUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-50481

Aeolus Pharmaceuticals Completes Senior Convertible Debt Financing

Contact: John L. McManus President and Chief Executive Officer 1-949-481-9825 Aeolus Pharmaceuticals Completes Senior Convertible Debt Financing LAGUNA NIGUEL, CA, August 1, 2008 - Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS), today announced that it has raised $500,000 through the sale of newly issued Senior Convertible Notes and warrants to selected institutional investors. The invest

SECURITIES PURCHASE AGREEMENT

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of August 1, 2008, by and among Aeolus Pharmaceuticals, Inc., a Delaware corporation with its headquarters located at 23811 Inverness Place, Laguna Niguel, California 92677, as issuer (the ?Company?), and the investors listed on the Schedule of Buyers attached hereto (individually, a ?Buyer? and c

[FORM OF NOTE FOR SUBSEQUENT CLOSINGS AND ELECTION CLOSINGS] SENIOR CONVERTIBLE NOTE

Exhibit 10.4 [FORM OF NOTE FOR SUBSEQUENT CLOSINGS AND ELECTION CLOSINGS] SENIOR CONVERTIBLE NOTE NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANS

Aeolus Pharmaceuticals Announces Third Quarter Fiscal Year 2008 Financial Results

Contact: John L. McManus President and Chief Executive Officer (949) 481-9825 Aeolus Pharmaceuticals Announces Third Quarter Fiscal Year 2008 Financial Results Laguna Niguel, California, August 4, 2008 - Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) announced today financial results for the three and nine months ended June 30, 2008. The Company reported a net loss of $580,000, or $0.02 p